Tag: sclc

Andarix Receives Orphan Drug Designation from the FDA for Small Cell Lung Cancer

Feb 16, 2014

—

by

cadams

in Article

lung cancer, oncology, orphan drug, personalized medicine, radiotherapy, sclc, small cell lung cancer, targeted therapy

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancers announced today that Tozaride, the Company’s targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC).